Greenberg Traurig Represents NeoImmuneTech, Inc. in KOSDAQ IPO
Share Article
Global law firm Greenberg Traurig, LLP represented NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, in connection with its initial public offering (IPO) on the Korea Exchange (KOSDAQ). WILMINGTON, Del. (PRWEB) April 01, 2021 Global law firm Greenberg Traurig, LLP represented NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, in connection with its initial public offering (IPO) on the Korea Exchange (KOSDAQ).
As part of the IPO, the company sold 3,133,334 shares of common stock, equivalent to 15,666,670 Korea Depository Receipts (KDRs), priced at KRW 37,500 per share. The aggregate gross proceeds to NeoImmuneTech, before deducting underwriting discounts and commissions and other offering expenses, were KRW 117.5 billion ($103.4 million). NeoImmuneTech trades under the KOSDAQ co